THE MINISTER OF STATE IN THE MINISTRY OF COMMERCE AND INDUSTRY (SHRI E. V. K. S. ELANGOVAN)
(a): Yes, Sir.
(b): The details of pending applications is as under:
S.No. Name of applicant Name of the product
1. Bayer Aktingesellschaft (Germany) Moxifloxacin Hydrochloride and Moxifloxacin Hydrochloride tablet equivalent to Moxifloxacia 400 mg.
2. Schering-Plough Corporation (United States of America). PEG-Interferon-alpha conjugates
3. Nicholas Piramal India Limited and Council of Scientific and Industrial Research (India) Bulaquine and Chloroquine Kit product.
4. Eli Lilly Company (United States of America). Tadalafil Tablet
5. F. Hoffman La Roche (Switzerland) Interferon Conjugates
6. Panacea Biotech Limited (India) Analgesic Composition Nimesulide Injection
(c): The details of applications which have been rejected is as under:
S.No. Name of applicant Name of the product
1. F. Hoffman La Roche A.G.(Switzerland) Saquinavir Mesylate equivalent to Saquinavir 200 mg. capsule
2. Smith Kline Beecham PLC(United Kingdom) Rosiglitazone Maleate tablet equivalent to 1 mg./2 mg./4 mg./8 mg. Rosiglitazone
3. Smith Kline Beecham PLC (United Kingdom). Rosiglitazone Maleate tablet equivalent to 1 mg./2 mg./4 mg./8 mg
4. Ranbaxy Laboratories Limited (India) Ciprofloxacine Composition
(d): The details of EMRs granted is as under:
S.No. Name of applicant Name of the product
1. United Phosphorus Limited (India) Syneqistic Fungicidal composition comprising carbendazim and mancozeb
2. Novartis AG, (Switzerland) Imatinib Mesilate
3. Wockhardt Limited (India) Nadifloxacin 1% Cream
